SG11201408028YA - METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES - Google Patents
METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVESInfo
- Publication number
- SG11201408028YA SG11201408028YA SG11201408028YA SG11201408028YA SG11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- serine protease
- california
- applicant
- rule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659821P | 2012-06-14 | 2012-06-14 | |
| PCT/US2013/045496 WO2013188587A1 (en) | 2012-06-14 | 2013-06-12 | METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408028YA true SG11201408028YA (en) | 2015-01-29 |
Family
ID=48700721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408028YA SG11201408028YA (en) | 2012-06-14 | 2013-06-12 | METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150239929A1 (es) |
| EP (1) | EP2861614B1 (es) |
| JP (1) | JP6261093B2 (es) |
| KR (2) | KR102100629B1 (es) |
| CN (1) | CN104379594B (es) |
| AU (1) | AU2013274288B2 (es) |
| CA (1) | CA2876361C (es) |
| ES (1) | ES2612458T3 (es) |
| HK (1) | HK1209760A1 (es) |
| IL (1) | IL235896B (es) |
| PT (1) | PT2861614T (es) |
| SG (1) | SG11201408028YA (es) |
| WO (1) | WO2013188587A1 (es) |
| ZA (1) | ZA201408921B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140346397A1 (en) | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| BE1022313B1 (nl) * | 2014-11-28 | 2016-03-15 | Puratos N.V. | Enzym-inhibitorcomplexen |
| SG11201810915QA (en) | 2016-06-17 | 2019-01-30 | Portola Pharm Inc | Preparation of factor xa derivatives |
| US20180037604A1 (en) * | 2016-08-04 | 2018-02-08 | Stelis Biopharma Private Limited | Process for the purification of recombinant proteins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8528321D0 (en) * | 1985-11-18 | 1985-12-24 | Ciba Geigy Ag | Modified fibrinolytic agents |
| KR960016514B1 (ko) * | 1990-10-12 | 1996-12-14 | 쿨리건 인터내셔널 컴패니 | 수도꼭지에 설치되는 미생물 필터 |
| CN1297896A (zh) * | 1999-11-29 | 2001-06-06 | 中国科学技术大学 | 一种高效提取活化的凝血因子X(FXa)的方法 |
| HUE052423T2 (hu) * | 2007-09-28 | 2021-04-28 | Alexion Pharma Inc | Az XA faktor inhibitorok antidótumai és ezek alkalmazási módszerei |
| DK2350271T3 (en) * | 2008-11-20 | 2016-04-04 | Biogen Ma Inc | ARGININ INACTIVATION OF ENVIRONMENT VIRA |
| PT2414517T (pt) * | 2009-03-30 | 2016-12-27 | Portola Pharm Inc | Antídotos para inibidores do fator xa e métodos de utilização dos mesmos |
| WO2010127980A1 (en) | 2009-05-05 | 2010-11-11 | F. Hoffmann-La Roche Ag | Fret-based binding assay |
-
2013
- 2013-06-12 CN CN201380033420.3A patent/CN104379594B/zh active Active
- 2013-06-12 PT PT137323176T patent/PT2861614T/pt unknown
- 2013-06-12 WO PCT/US2013/045496 patent/WO2013188587A1/en active Application Filing
- 2013-06-12 ES ES13732317.6T patent/ES2612458T3/es active Active
- 2013-06-12 JP JP2015517406A patent/JP6261093B2/ja active Active
- 2013-06-12 CA CA2876361A patent/CA2876361C/en active Active
- 2013-06-12 SG SG11201408028YA patent/SG11201408028YA/en unknown
- 2013-06-12 KR KR1020147036450A patent/KR102100629B1/ko active IP Right Grant
- 2013-06-12 AU AU2013274288A patent/AU2013274288B2/en active Active
- 2013-06-12 US US14/406,645 patent/US20150239929A1/en not_active Abandoned
- 2013-06-12 EP EP13732317.6A patent/EP2861614B1/en active Active
- 2013-06-12 KR KR1020207010091A patent/KR102210574B1/ko active IP Right Grant
-
2014
- 2014-11-25 IL IL235896A patent/IL235896B/en active IP Right Grant
- 2014-12-04 ZA ZA2014/08921A patent/ZA201408921B/en unknown
-
2015
- 2015-10-20 HK HK15110322.1A patent/HK1209760A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2612458T3 (es) | 2017-05-17 |
| HK1209760A1 (en) | 2016-04-08 |
| CA2876361A1 (en) | 2013-12-19 |
| JP6261093B2 (ja) | 2018-01-17 |
| US20150239929A1 (en) | 2015-08-27 |
| KR102210574B1 (ko) | 2021-02-01 |
| PT2861614T (pt) | 2017-01-26 |
| EP2861614A1 (en) | 2015-04-22 |
| KR102100629B1 (ko) | 2020-04-16 |
| KR20150027765A (ko) | 2015-03-12 |
| WO2013188587A1 (en) | 2013-12-19 |
| IL235896A0 (en) | 2015-01-29 |
| AU2013274288A1 (en) | 2015-01-15 |
| CA2876361C (en) | 2020-06-30 |
| ZA201408921B (en) | 2020-08-26 |
| CN104379594A (zh) | 2015-02-25 |
| IL235896B (en) | 2019-02-28 |
| JP2015521471A (ja) | 2015-07-30 |
| CN104379594B (zh) | 2017-06-23 |
| KR20200039828A (ko) | 2020-04-16 |
| EP2861614B1 (en) | 2016-11-30 |
| AU2013274288B2 (en) | 2017-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| SG11201408261UA (en) | Syringe | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201804309PA (en) | Antibody molecules to april and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201408028YA (en) | METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201407674TA (en) | D-amino acid compounds for liver disease | |
| SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201406625XA (en) | Anti-fcrn antibodies | |
| SG11201407372UA (en) | Nampt inhibitors | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |